Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | a small-molecule pocket: trenonacog alfa, valoctocogene roxaparvovec, fidanacogene elaparvovec +9 | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 3,357 | 0.79 |
| pathways Reactome | 14 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 16653
Sealed predictions
- F9 in dopamine neurons, braak+0.60 (p 0.090) → -0.13 (p 0.735)receipt 16660
Swarm cases
receipt 16660: F9 in dopamine neurons, braak
- power
- full sample +0.15 (p 0.555, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.235, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.046, n 18). not the mix.
- skeptic
- leave-one-out range +0.02 to +0.28, sign flips 0; without severely affected donors +0.15 (p 0.555, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for F9 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts